Immutep Limited (ASX:IMM) Announces Positive Phase I Results for IMP761
Study Results
Immutep reported significant T cell suppression and a favourable safety profile at a dosing level of 0.9 mg/kg in its Phase I trial of IMP761, a first-in-class LAG-3 agonist antibody for autoimmune diseases. The inhibition of T cell infiltration in the skin reached 80% at day 10 post-neoantigen rechallenge. The company will continue with single ascending dose levels of 2.5, 7, and 14 mg/kg.
Future Developments
Additional data from the Phase I study is expected in the second half of CY2025.
Executive Comments
Dr. Frédéric Triebel, CSO of Immutep, stated, “The early pharmacological data showing substantial T cell suppression at the highest dose level of IMP761 are very promising, especially in conjunction with its continued favourable safety profile, and highlight the potential efficacy of this LAG-3 agonist in treating autoimmune diseases. LAG-3 expression on activated T cells is known to be highly specific to disease sites, and particularly in areas of chronic inflammation. This unique specificity enables the potential for IMP761 to have a more targeted approach with fewer side effects than other therapies. We look forward to evaluating higher dosing levels of IMP761 and hope to further enhance its ability to safely silence the dysregulated T cells responsible for many autoimmune diseases.”
Motley Fool contributor Lauren Surplice has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.
